Breast Cancer
Researchers from the United States and Germany provide details of new studies and findings in the area of breast cancer
Published in Women's Health Weekly, May 1st, 2006
Study 1: According to recent research from the United States, truncated Bid gene therapy targets breast cancer.
"We studied the efficiency of the proapoptotic factor tBid, targeted to tumor cells using the promoters of the hTERT, Survivin and Muc1 genes, in killing breast cancer cells," wrote I. Kazhdan and colleagues, University of Texas, San Antonio.
"tBid is the active fragment of the proapoptotic protein Bid and is generated in response to death receptor activation. When placed under control of a strong CMV promoter, tBid was highly efficient...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Atherosclerosis
Atherosclerosis risk may be reduced by weight loss-induced changes in cathepsin S level - Breast Cancer
Breast cancer risk may be increased with lifetime moderate alcohol intake - Neurology
Migraine prevalence in women may be due to changes in endocannabinoid system - Osteoporosis
Bone mineral density may be improved by adding vitamin K2 to calcium supplementation - Pre-eclampsia
Pre-eclampsia severity, but not incidence, may be reduced with calcium supplementation - Acne
New free teen beauty guide keeps pimples away from the prom - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
